NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-38155
Issuer: Sienna Biopharmaceuticals, Inc.
Exchange: The Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 30699 Russell Ranch Road
Suite 140
Westlake Village CALIFORNIA 91362
Telephone number: (818) 629-2256
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2020-02-05 By Aravind Menon Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Delisting Determination, The Nasdaq Stock Market, LLC,
February 4, 2020, Sienna Biopharmaceuticals, Inc. The
Nasdaq Stock Market LLC (the Exchange) has determined to
remove from listing the common stock of Approach Resources
Inc. (the Company), effective at the opening of the trading
session on February 14, 2020. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Rules 5101, 5110(b), and IM-5101-1.
The Company was notified of the Staff determination on
September 17, 2019.  The Company appealed the determination
to a Hearing Panel on September 24, 2019. On November 12,
2019, the Hearing Panel determined to continue the Company
listing subject to certain milestones. On December 11, 2019,
the company informed of its decision to withdraw from the
hearing process. The Listing Council did not call the matter
for review. The Staff determination to delist the Company
became final on January 27, 2020.